The aAPC platform was used to rapidly amplify tumour-infiltrating lymphocytes from primary tumour specimens, based on the Carl H June designed aAPC-K32, and further co-transfection with co-stimulatory molecule 4-1BBL and allowing it to secrete IL-2, IL-15, or IL-21 cytokines [116]. Here, IL21 is linked to neoplasm.